海南海药股价下跌1.27% 氟非尼酮Ⅱ期临床数据正在分析

Core Viewpoint - Hainan Haiyao's stock price decreased by 1.27% to 6.20 yuan on August 13, with a trading volume of 450,581 hands and a transaction amount of 279 million yuan [1] Company Overview - Hainan Haiyao operates in the chemical pharmaceutical industry, focusing on drug research, production, and sales. The product line includes antibiotics, anti-tumor drugs, and cardiovascular medications [1] Clinical Development - The company is currently conducting phase II clinical data analysis for Fluorofenone [1] Product Inclusion in National Procurement - Three of the company's drugs, including injectable Cefazolin Sodium, Rosuvastatin Capsules, and Desloratadine Oral Solution, have been included in the National Medical Insurance Administration's 11th batch of centralized procurement [1] Capital Flow - On August 13, the net outflow of main funds was 29.35 million yuan, with a cumulative net outflow of 97.31 million yuan over the past five days [1]